Cf Therapeutics Development Network is categorized under Medical Research in Seattle, WA and active since 2006.
Cf Therapeutics Development Network was established in 2006, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Raissa Schneider at the company’s single location by writing to 1100 Olive Way # 500, Seattle, Washington WA 98101 or by phoning (206) 987-7800. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Cf Therapeutics Development Network |
| Contact Person: | Raissa Schneider |
| Address: | 1100 Olive Way # 500, Seattle, Washington 98101 |
| Phone Number: | (206) 987-7800 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2006 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Cf Therapeutics Development Network was started in 2006 to provide professional Medical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Raissa Schneider for inquiries that concern Cf Therapeutics Development Network by calling the company number (206) 987-7800, as your correspondence is most welcome. Additionally, the physical location of the single location of Cf Therapeutics Development Network can be found at the coordinates as well as the street address 1100 Olive Way # 500 in Seattle, Washington 98101.
For its online presence, you may visit Cf Therapeutics Development Network’s website at and engage with its social media outlets through on Twitter and on Facebook.